Golden State Equity Partners Grows Position in Kenvue Inc. (NYSE:KVUE)

Golden State Equity Partners increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 12.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 27,262 shares of the company’s stock after buying an additional 3,004 shares during the period. Golden State Equity Partners’ holdings in Kenvue were worth $587,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Clearstead Advisors LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $27,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. Global Retirement Partners LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Kenvue in the third quarter valued at approximately $28,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on KVUE. Sanford C. Bernstein began coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. William Blair began coverage on Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating for the company. The Goldman Sachs Group began coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price target for the company. Royal Bank of Canada cut their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Finally, JPMorgan Chase & Co. cut their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $24.85.

Kenvue Stock Performance

Shares of KVUE stock traded down $0.16 during mid-day trading on Friday, reaching $18.86. The stock had a trading volume of 15,454,689 shares, compared to its average volume of 13,458,618. Kenvue Inc. has a 12-month low of $17.82 and a 12-month high of $27.80. The business has a 50-day simple moving average of $19.84 and a 200 day simple moving average of $20.13. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. The company’s revenue was down 2.7% on a year-over-year basis. Research analysts expect that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 4.24%. The ex-dividend date of this dividend is Tuesday, May 7th.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.